visceral adiposity comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Classification of nerve damage was well-defined by Sir Herbert Seddon and Sunderland in a system that remains in use. The adjacent table details the forms (neurapraxia, axonotmesis and neurotmesis) and degrees of nerve injury that occur as a result of exposure to various temperatures, with the intent to interrupt nerve traffic and relieve pain. Cryoneurolysis treatments that use nitrous oxide (boiling point of −88.5 °C) as the coolant fall in the range of an axonotmesis injury, or 2nd degree injury, according to the Sunderland classification system. Treatments of the nerve in this temperature range are reversible, usually within a few months. Nerves treated in this temperature range experience a disruption of the axon, with Wallerian degeneration occurring distal to the site of injury. The axon and myelin sheath are affected, but all of the connective tissues (endoneurium, perineurium, and epineurium) remain intact. Following Wallerian degeneration, the axon regenerates along the original nerve path at a rate of approximately 1–2 mm per day. Cryoneurolysis differs from cryoablation in that cryoablation treatments use liquid nitrogen (boiling point of −195.8 °C) as the coolant, and therefore, fall into the range of a neurotmesis injury, or 3rd degree injury according to the Sunderland classification. Treatments of the nerve in this temperature range are irreversible. Nerves treated in this temperature range experience a disruption of both the axon and the endoneurium connective tissue layer.
The largest risk of relapse occurs within the first year post-discharge from eating disorder therapy treatment. Within the first two years post-discharge, approximately 31% of anorexia nervosa patients relapse. Many complications, both physical and psychological, improve or resolve with nutritional rehabilitation and adequate weight gain. Anorexia nervosa is estimated to occur in approximately 0.3–4.3% of women and 0.2–1% of men in Western countries at some point in their life. Levels in other countries are unclear due to undiagnosis and a lack of awareness, though it can be presumed it is more present in Western societies due to a higher focus on low body weight and beauty on social media and real life. There is an observation for an increase in the diagnosis of anorexia from the 20th century onwards: it is unclear whether this is due to an actual increase in its frequency or simply due to improved diagnostic capabilities. In 2013, it directly resulted in about 600 deaths globally, up from 400 deaths in 1990. Eating disorders also increase a person's risk of death from a wide range of other causes, including suicide. About 5% of people with anorexia die from complications over a ten-year period with medical complications and suicide being the primary and secondary causes of death respectively. Anorexia has one of the highest death rates among mental illnesses, second only to opioid overdoses.
=== Medications === Medications that lower fevers are called antipyretics. The antipyretic ibuprofen is effective in reducing fevers in children. It is more effective than acetaminophen (paracetamol) in children. Ibuprofen and acetaminophen may safely be used together in children with fevers. The efficacy of acetaminophen by itself in children with fevers has been questioned. Ibuprofen is also superior to aspirin in children with fevers. Additionally, aspirin is not recommended in those under the age of 18 due to the risk of Reye's syndrome. Using both paracetamol and ibuprofen at the same time or alternating between the two is more effective at decreasing fever than using only paracetamol or ibuprofen. It is not clear if it increases child comfort. Response or nonresponse to medications does not predict whether or not a child has a serious illness. With respect to the effect of antipyretics on the risk of death in those with infection, studies have found mixed results, as of 2019.
Sources: en.wikipedia.org
Josh Allen became the first player to score a rushing touchdown, a receiving touchdown and multiple passing touchdowns in a single game. Bobby Wagner extended his streak of recording 100 tackles in a season to 13 years. He is the second player to record the feat, joining London Fletcher. Jayden Daniels became the first rookie to complete 80 percent of his passes, throw three touchdowns, and run for a touchdown in a single game. Jameis Winston became the first player in the Super Bowl era to have at least 400 passing yards, four passing touchdowns and two interceptions returned for touchdowns in a game. Justin Herbert became the third player to have at least 10 consecutive games without interception (minimum 15 attempts per game), joining Tom Brady and Derek Carr. The Pittsburgh Steelers tied the record for most consecutive seasons finishing with a winning percentage of .500 or better, with 21. They share the record with the Dallas Cowboys, who did so from 1965 to 1985. The Cincinnati Bengals tied the single-season record for most games lost while scoring at least 30 points, with four. They share the record with the 2002 Kansas City Chiefs. Week 14
"A/B testing" is a shorthand for a simple randomized controlled experiment, in which a number of samples (e.g. A and B) of a single vector-variable are compared. A/B tests are widely considered the simplest form of controlled experiment, especially when they only involve two variants. However, by adding more variants to the test, its complexity grows. The following example illustrates an A/B test with a single variable: A company has a customer database of 2,000 people and launches an email campaign with a discount code in order to generate sales through its website. The company creates two versions of the email with different calls to action (the part of the copy that encourages customers to act—in the case of a sales campaign, make a purchase) and identifying promotional codes.
An NTP binding site is a type of binding site found in nucleoside monophosphate (NMP) kinases, N can be adenosine or guanosine. A P-loop is one of the structural motifs common for nucleoside triphosphate (NTP) binding sites, it interacts with the bound nucleotide's phosphoryl groups. For the binding site to be able to bind a nucleotide, the nucleotide must be complex bound to Mg2+ or Mn2+. Nucleotide binding will cause conformational changes in the protein because the P-loop will bend. NTP binding sites play a role in poliovirus RNA replication. On the poliovirus RNA-dependent polymerase, also known as 3Dpol, there are two binding sites. Both binding sites contain lysine residues; however, only the lysine at position 61 is essential for RNA sequence elongation as part of the replication process. Additionally, a method known as computational alanine mutagenesis, has been used to find the key portions within the amino acid sequences that majorly characterize a particular NTP binding site; these regions within the sequence are conserved.
Sources: en.wikipedia.org
The goal of cheese making is to control the spoiling of milk into cheese. The milk is traditionally from a cow, goat, sheep, or buffalo, although, in theory, cheese could be made from the milk of any mammal. Cow's milk is most commonly used worldwide. The cheesemaker's goal is a consistent product with specific characteristics (appearance, aroma, taste, texture). The process used to make a Camembert will be similar to, but not quite the same as, that used to make Cheddar. Some cheeses may be deliberately left to ferment from naturally airborne spores and bacteria; this approach generally leads to a less consistent product but one that is valuable in a niche market.
The Sanitary Board was established in 1883 in responsible of improving the sanitary conditions in the city as the result of Osbert Chadwick's report in 1881 advised. Under the 1887 Public Health Ordinance, the Board was composed of four official members and no more than six unofficial members, and that four official members should be appointed by the Governor (two of them being Chinese) and two elected by the ratepayers who were on the jury lists of the election year. Three elections were held in 1888, 1891 and 1894 respectively. The bubonic plague of 1894 raised the question of the composition and powers of the Board. The Government's decision of appointing a Medical Officer of Health to the Board in 1895 was against the will of the unofficial members. J. J. Francis, the three times elected member resigned, and other three unofficial members Ho Kai, William Hartigan and Robert Kennaway Leigh followed. The members of the Executive Council and the Chamber of Commerce were dissatisfied the sanitation and ineffectiveness of the Board. Prominent leaders including J. J. Keswick of the Chamber of Commerce, Paul Chater and E. R. Belilios were in favour of an official majority while the officers directly responsible to the Governor. Contrast to the abolition of the Board, Ho Kai represented another opinion of maintaining the unofficial majority and larger power of the unofficial members.
By inhibiting LL-37 expression, doxycycline helps to mitigate these downstream inflammatory cascades, thereby reducing inflammation and the symptoms of inflammatory conditions. Doxycycline is used to treat acne vulgaris and rosacea. However, there is no clear understanding of what contributes more: the bacteriostatic properties of doxycycline, which affect bacteria (such as Propionibacterium acnes) on the surface of sebaceous glands even in lower doses called "submicrobial" or "subantimicrobial", or whether doxycycline's anti-inflammatory effects, which reduce inflammation in acne vulgaris and rosacea, including ocular rosacea, contribute more to its therapeutic effectiveness against these skin conditions. Subantimicrobial-dose doxycycline (SDD) can still have a bacteriostatic effect, especially when taken for extended periods, such as several months in treating acne and rosacea. While the SDD is believed to have anti-inflammatory effects rather than solely antibacterial effects, SDD was proven to work by reducing inflammation associated with acne and rosacea. Still, the exact mechanisms have yet to be fully discovered. One probable mechanism is doxycycline's ability to decrease the amount of reactive oxygen species (ROS). Inflammation in rosacea may be associated with increased production of ROS by inflammatory cells; these ROS contribute toward exacerbating symptoms.
Protein phosphorylation is highly conserved in pathways central to cell survival, such as cell cycle progression relying on cyclin-dependent kinases (CDKs), but individual phosphorylation sites are often flexible. Targets of CDK phosphorylation often have phosphosites in disordered segments, which are found in non-identical locations even in close species. Conversely, targets of CDK phosphorylation in structurally defined regions are more highly conserved. While CDK activity is critical for cell growth and survival in all eukaryotes, only very few phosphosites show strong conservation of their precise positions. Positioning is likely to be highly important for phosphates that allosterically regulate protein structure, but much more flexible for phosphates that interact with phosphopeptide-binding domains to recruit regulatory proteins.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.